Zbtb32 overexpression enhances CD8 + T cell anti-tumor rejection. (A) Quantifications of specific genes expressions in WT, Zbtb32 OE activated CD8+ T cells measured by RT-qPCR (n = 3 for each group). (B) Schematic diagram of the transfer with 7 × 105 transduced OT-I or P14 cells on day 8. (C) Tumor growth in mice transferred with 7 × 105 activated Zbtb32 OE or RV control CD8+ OT-I cells on 8 days after 1 × 106 B16-OVA cells inoculation (n = 6 for each group). (D) Survival rate in mice transferred with 7 × 105 activated Zbtb32 OE or RV control CD8+ OT-I cells on day 8 after 1 × 106 B16-OVA cells inoculation (n = 6 for each group). (E) Representative plots of TCF1 and Tim-3, IFNγ and GzmB in RV control, and Zbtb32 OE CD8+ OT-I TILs in B16-OVA TME. (F) Quantifications of specific molecules in RV control and Zbtb32 OE CD8+ OT-I TILs in B16-OVA TME (n = 6 for each group). Data are shown as means ± SEM; ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by unpaired (A and F) two-tailed Student’s t test, Bonferroni-corrected two-way ANOVA (C), and Mantel–Cox test (D). Data shown in all graphs are a representative of three independent experiments.